| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Application of the euglycaemic clamp technique to bioassay of insulin analogues
|
Vølund, A.
|
|
1992
|
20 |
2 |
p. 135-142
8 p.
|
artikel
|
| 2 |
Detoxification of diphtheria and tetanus toxin with formaldehyde. detection of protein conjugates
|
Aggerbeck, Henrik
|
|
1992
|
20 |
2 |
p. 109-115
7 p.
|
artikel
|
| 3 |
International workshop: ‘Poliovirus attenuation: Molecular mechanisms and practical aspects’
|
Ehrenfeld, Ellie
|
|
1992
|
20 |
2 |
p. 167-169
3 p.
|
artikel
|
| 4 |
Note for guidance
|
Committee for Proprietary Medicinal Products: Ad Hoc Working Party on Biotechnology/Pharmacy and Working Party on Safety Medicines,
|
|
1992
|
20 |
2 |
p. 159-164
6 p.
|
artikel
|
| 5 |
Note for guidance
|
Committee for Proprietary Medicinal Products: Ad Hoc Working Party on Biotechnology/Pharmacy and Working Party on Safety Medicines,
|
|
1992
|
20 |
2 |
p. 155-158
4 p.
|
artikel
|
| 6 |
Obituary—Jean-Pierre Lecocq 1947–1992
|
Horaud, Florian
|
|
1992
|
20 |
2 |
p. 89-
1 p.
|
artikel
|
| 7 |
Potency assays for anistreplase: Comparison of the fibrin plate assay and a 96-well plate assay
|
Beebe, Deborah P.
|
|
1992
|
20 |
2 |
p. 129-133
5 p.
|
artikel
|
| 8 |
Quantitative estimation of diphtheria and tetanus toxoids. 6. Use of different antibody titration methods for evaluation of immunogenicity in animals during potency assay of diphtheria toxoid
|
Lyng, Jørn
|
|
1992
|
20 |
2 |
p. 101-108
8 p.
|
artikel
|
| 9 |
Report of a collaborative study to assess the determination of glycoprotein antigen content of rabies vaccines for human use
|
Ferguson, Morag
|
|
1992
|
20 |
2 |
p. 143-154
12 p.
|
artikel
|
| 10 |
Safety aspects in the manufacturing of plasma-derived coagulation factor concentrates
|
Burnouf, Thierry
|
|
1992
|
20 |
2 |
p. 91-100
10 p.
|
artikel
|
| 11 |
Variation in the biological function of envelope protein epitopes of yellow fever vaccine viruses detected with monoclonal antibodies
|
Ledger, T.N.
|
|
1992
|
20 |
2 |
p. 117-128
12 p.
|
artikel
|
| 12 |
Views on the issues raised in recent letters by Galibert recommending studies for genetic stability testing of cells used to manufacture purified polypeptide pharmaceutical products utilizing recombinant DNA (rDNA) technology
|
Committee on Process Development and Manufacturing,
|
|
1992
|
20 |
2 |
p. 165-166
2 p.
|
artikel
|
Tijdschrift beschrijving